Kras-driven murine lung cancers were particularly susceptible to CDK4 ablation, and a sustained tumor response was achieved with concomitant CDK4 inactivation and RAF1 ablation in Kras/p53-driven murine lung cancers (16, 17). This evidence concerns the gene KRAS and lung cancer.